Immune microenvironment of tumor-draining lymph nodes: insights for immunotherapy

Uloženo v:
Podrobná bibliografie
Vydáno v:Frontiers in Immunology vol. 16 (Apr 2025), p. 1562797-1562807
Hlavní autor: Jiahuan Wei
Další autoři: Li, Daozhang, Long, Haixia, Han, Mei
Vydáno:
Frontiers Media SA
Témata:
On-line přístup:Citation/Abstract
Full Text
Full Text - PDF
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

MARC

LEADER 00000nab a2200000uu 4500
001 3278271839
003 UK-CbPIL
022 |a 1664-3224 
024 7 |a 10.3389/fimmu.2025.1562797  |2 doi 
035 |a 3278271839 
045 2 |b d20250401  |b d20250430 
100 1 |a Jiahuan Wei  |u School of Pharmacy and Bioengineering, Chongqing University of Technology, Chongqing, China 
245 1 |a Immune microenvironment of tumor-draining lymph nodes: insights for immunotherapy 
260 |b Frontiers Media SA  |c Apr 2025 
513 |a Journal Article 
520 3 |a Tumor-draining lymph nodes (TDLNs) play a crucial role in modulating tumor immune responses and influencing the efficacy of immunotherapy. However, our current understanding of the microenvironment within these lymph nodes remains limited. Tumors not only impair the anti-tumor activity of CD8+ T cells by creating an immunosuppressive microenvironment, but they also facilitate immune evasion and promote metastasis by altering the structure and function of TDLNs. Research has shown that tumor-specific memory CD8+ T cells (TTSM) within TDLNs are essential for the efficacy of immune checkpoint inhibitors, such as PD-1/PD-L1 blockers. Moreover, the abnormal structure of TDLNs, along with the presence of immunosuppressive cells—such as regulatory T cells (Tregs), regulatory B cells (Bregs), and immunosuppressive dendritic cells (DCs)—contributes to tumor-mediated immune evasion. Therefore, gaining a deeper understanding of the immune microenvironment within TDLNs is essential for improving the effectiveness of immunotherapies and developing novel therapeutic strategies. This review explores various TDLN-based therapeutic strategies, addressing the controversies surrounding lymph node dissection, the use of TDLNs as a source of tumor-infiltrating lymphocytes (TILs) for therapy, targeting immunosuppressive cells within TDLNs, and methods to reverse the structural abnormalities of TDLNs. These strategies offer valuable insights and potential directions for advancing tumor immunotherapy. 
653 |a Cancer 
653 |a PD-L1 protein 
653 |a Metastasis 
653 |a Immunoregulation 
653 |a Immunotherapy 
653 |a Immune checkpoint inhibitors 
653 |a Lymphocytes T 
653 |a Metastases 
653 |a Immunological memory 
653 |a Immunity (Disease) 
653 |a Immune system 
653 |a Lymphatic system 
653 |a Memory cells 
653 |a Immune response 
653 |a Tumor-infiltrating lymphocytes 
653 |a Lymphocytes 
653 |a Immunosuppressive agents 
653 |a Dendritic cells 
653 |a PD-1 protein 
653 |a Antigens 
653 |a Microenvironments 
653 |a Tumors 
653 |a Lymph nodes 
653 |a Structure-function relationships 
653 |a Lymphocytes B 
653 |a CD8 antigen 
653 |a Antitumor agents 
653 |a Immune evasion 
700 1 |a Li, Daozhang  |u Institute of Cancer, Xinqiao Hospital, Third Military Medical University, Chongqing, China 
700 1 |a Long, Haixia  |u School of Pharmacy and Bioengineering, Chongqing University of Technology, Chongqing, China 
700 1 |a Han, Mei  |u Department of Gynecologic Oncology, Chongqing University Cancer Hospital & Chongqing Cancer Institute & Chongqing Cancer Hospital, Chongqing, China 
773 0 |t Frontiers in Immunology  |g vol. 16 (Apr 2025), p. 1562797-1562807 
786 0 |d ProQuest  |t Health & Medical Collection 
856 4 1 |3 Citation/Abstract  |u https://www.proquest.com/docview/3278271839/abstract/embedded/75I98GEZK8WCJMPQ?source=fedsrch 
856 4 0 |3 Full Text  |u https://www.proquest.com/docview/3278271839/fulltext/embedded/75I98GEZK8WCJMPQ?source=fedsrch 
856 4 0 |3 Full Text - PDF  |u https://www.proquest.com/docview/3278271839/fulltextPDF/embedded/75I98GEZK8WCJMPQ?source=fedsrch